Biogenerics: Potential benefits and obstacles

Consultant Pharmacist

Volumn 21, Issue 3, 2006, Pages 208-221

  Wick, Jeannette Y ^a   Zanni, Guido R ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

Biogeneric; Biosimilars; Drug approval process; Follow on biologics; Generic; Glycosylation

Indexed keywords

ABCIXIMAB; ALPHA INTERFERON; BIOLOGICAL PRODUCT; BIOLOGICAL RESPONSE MODIFIER; BLOOD CLOTTING FACTOR 8; CONJUGATED ESTROGEN; ENZYME; ETANERCEPT; GANIRELIX; GENERIC DRUG; GLUCAGON; HEPATITIS B VACCINE; HORMONE; HUMAN GROWTH HORMONE; HUMAN INSULIN; INSULIN; MONOCLONAL ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMNITROPE; PEPTIDE; PROTEIN; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; SUGAR; TISSUE PLASMINOGEN ACTIVATOR; VACCINE;

BIOEQUIVALENCE; BIOTECHNOLOGY; CELL LINE; COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; GLYCOSYLATION; HUMAN; KIDNEY DISEASE; LAW SUIT; NONHUMAN; PATENT; PHARMACEUTICAL ENGINEERING; PHARMACIST; PRESCRIPTION; PURE RED CELL ANEMIA; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 33645082463     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2006.208     Document Type: Review

References (14)

1. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med 2005;142:891-7.
2. U.S. Food and Drug Administration. Savings from generic drugs purchased at retail pharmacies. Available at http://www.fda.gov/cder/consumerinfo/ savingsfromgenericdrugs.htm. Accessed December 1, 2005.
3. Kirking DM, Gaither CA, Ascione FJ et al. Pharmacists' individual and organizational views on generic medications. J Am Pharm Assoc 2001;41:567-77.
4. Faden M. Biogenerics hang at the starting gate. Generic biopharmaceutical makers seek short-cut approvals from FDA. Pharmaceutical Business Strategies March 2005. Available at http://www.pbsmag.com/Article.cfm?ID=169. Accessed December 5, 2005.
5. Crommelin DJ, Storm G, Verrijk R et al. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003;266:3-16.
6. Humphreys A. Difficult path for biogenerics. Med Ad News 2004;23:1-6.
7. Charles SA. SuperGenerics: a better alternative for biogenerics. Drug Discov Today 2005;10:533-5.
8. McCook A. Manufacturing on a grand scale. The Scientist February 14, 2005:34-58.
9. Abboud L. Start-up tries path to making biotech clones. The Wall Street Journal Europe August 17, 2005:A5.
10. Louet S. Lessons from Eprex for biogeneric firms. Nat Biotechnol 2003;21:956-7.
11. Herrera S. Biogenerics standoff. Nat Biotechnol 2004;22:1343-6.
12. Fox JL. Sandoz sues FDA over delay in first biogeneric approval. Nat Biotechnol 2005;23:1327-8.
13. Hirschler B. FDA rebuffs Novartis over delay to biogeneric drug. Reuters Regulatory News Available at http://yahoo.reuters/com/financeNewsArticle.jhtml? type=government. Accessed December 1, 2005.
14. U.S. Food and Drug Administration Center for Drug Evaluation and Research. FDA statement on generic Premarin. May 5, 1997. Available at http://www.fda.gov/cder/news/cepressrelease.htm. Accessed November 28, 2005.